Lithium Augmentation in Antidepressant-Resistant Patients a Quantitative Analysis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A quantitative analysis was used to examine the efficacy of lithium augmentation in the acute treatment of depressed patients resistant to a standard trial of an antidepressant. Effect sizes were measured by the odds ratio using the Mantel–Haenszel method. Only controlled trials were included in order to minimise bias in method. A highly statistically significant effect for lithium augmentation was found, the pooled odds ratio being 0.146 and its 95% confidence interval 0.05–0.44 (i.e. the odds of remaining ill are reduced by between 56% and 95% with the use of lithium treatment). While these results support the case for lithium augmentation in treatment-resistant depression, there remains considerable uncertainty over the duration of treatment necessary to see and sustain the treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“For the effect size, the odds ratio together with its associated confidence interval has been advocated as both intuitively comprehensible and statistically elegant (Yusuf et al,1985).”
Background
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Anderson, I. M., Nutt, D. J., & Deakin, J. F. W. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400101 · Cited by 310
Lithium Augmentation in Treatment-Resistant Depression: Meta-Analysis of Placebo-Controlled Studies
Bauer, M., & Döpfmer, S. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00006 · Cited by 304
Joffe, R. T. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820170065008 · Cited by 258
The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics
O’Donnell, K. C., & Gould, T. D. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.04.002 · Cited by 137
Economic implications of treatment-resistant depression among employees
Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422060-00003 · Cited by 113
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
“Second-line recommendations APA included lithium with Level II (moderate) confidence and stated that it is the most widely studied adjunctive treatment for this patient group, has the potential to reduce the risk of suicide, and has efficacy in preventing relapse (Austin et al., 1991; Bauer and Dopfmer, 1999; Cipriani…”
BackgroundHaj-Mirzaian, A., Amiri, S., Kordjazy, N., Momeny, M., Razmi, A., Rahimi-Balaei, M., Amini-Khoei, H., Haj-Mirzaian, A., Marzban, H., Mehr, S. E., et al. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.024 · Cited by 46
McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089042 · Cited by 12
Metadata
- Authors
- Austin, M.-P. V., Souza, F. G. M., & Goodwin, G. M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1991-10
- Volume
- 159
- Issue
- 4
- Pages
- 510-514
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2114743098
- Cited by
- 97
- References
- 1
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.